Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series.

Abstract

Treatment with immunomodulators, such as intravenous immunoglobulin (IVIG), may attenuate inflammatory responses observed in the severe stages of acute respiratory distress syndrome (ARDS) caused by coronavirus disease 19 (COVID-19). We retrospectively evaluated the clinical courses of 12 COVID-19 patients who received IVIG at various stages of their illness, including within the first 72 h of clinical presentation, after initiation of mechanical ventilation, and after prolonged ventilation and ICU stay. The patients included 9 men and 3 women with a median age of 50 years (range 23-74), median Charlson Comorbidity Score of 2 (range 0-7), and median Acute Physiology and Chronic Health Evaluation Score of 13 (range 5-33) at the time of IVIG. The IVIG total dose ranged from 0.5 to 2.0 g/kg (median 1.25 g/kg) distributed over 1-4 daily doses. The most common regimen received was 0.5 g/kg daily for 3 days. The median time to IVIG administration was 9 days (range 0-48 days) after admission. The median time from first IVIG dose administration to hospital discharge was 14 days (range 3-48). The 5 patients who received IVIG ≤4 days of admission demonstrated a significantly shorter length of hospital stay after treatment (median 7 days, range 3-14 days) than the 7 patients who received it >7 days after admission (median 33 days, range 8-48 days, p = 0.03, Mann-Whitney U test). These cases demonstrate that IVIG may improve the clinical state of patients with moderate to severe COVID-19 infection. Despite very high illness severity scores, all patients survived hospital discharge. No thrombotic events occurred and IVIG was well tolerated, despite most cases demonstrating very elevated D-dimer suggestive of active intravascular fibrinolysis. We believe that IVIG warrants immediate clinical trial evaluation in COVID-19 to confirm its role as a mainstay treatment of moderate to severe COVID-19 infection as a means to reduce hospital stay and utilization of ICU resources, including mechanical ventilation, and potentially reduce mortality.

• Authors: Felix J F Herth, George Sakoulas, Fadi Haddad
• Journal: Respiration; international review of thoracic diseases (Respiration) Vol. 99 Issue 12 Pg. 1145-1153 ( 2020) ISSN: 1423-0356 [Electronic] Switzerland
• PMID: 33316806 (Publication Type: Journal Article, Observational Study)
• Copyright: © 2020 The Author(s) Published by S. Karger AG, Basel.

Chemical References

• Adrenal Cortex Hormones
• Anti-Bacterial Agents
• Antibodies, Monoclonal, Humanized
• Antiviral Agents
• Enzyme Inhibitors
• Immunoglobulins, Intravenous
• Immunologic Factors
• Octagam
• Lopinavir
• remdesivir
• Adenosine Monophosphate
• Hydroxychloroquine
• Azithromycin
• tocilizumab
• Doxycycline
• Alanine

Topics

• APACHE
• Adenosine Monophosphate (analogs & derivatives, therapeutic use)
• Adrenal Cortex Hormones (therapeutic use)
• Adult
• Aged
• Alanine (analogs & derivatives, therapeutic use)
• Anti-Bacterial Agents (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antiviral Agents (therapeutic use)
• Azithromycin (therapeutic use)
• COVID-19 (therapy)
• Doxycycline (therapeutic use)
• Enzyme Inhibitors (therapeutic use)
• Extracorporeal Membrane Oxygenation
• Female
• Humans
• Hydroxychloroquine (therapeutic use)
• Immunoglobulins, Intravenous (therapeutic use)
• Immunologic Factors (therapeutic use)
• Intensive Care Units
• Length of Stay
• Lopinavir (therapeutic use)
• Male
• Middle Aged
• Respiration, Artificial
• Retrospective Studies
• Severity of Illness Index
• Time Factors
• Young Adult
• COVID-19 Drug Treatment